ONCO
Onconetix, Inc. Common Stock
stock NASDAQ

developed by scientists at the prestigious oxford university in the uk, our vaccine protects against all influenza strains. it targets parts of the virus that are easy to induce a protective immune response against but also limited in variability. these regions of the virus were shown in thompson et al 2018 to direct the antigenic evolution of the influenza virus and therefore make ideal vaccine targets. the vaccine thus negates the need for (i) annual vaccination, providing potentially life-long protection against flu, and (ii) reformulation of the vaccine every few years.